Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 359 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
359 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with homozygous MTAP-deleted solid tumors (ECOG 0–1) receive oral BAY 3713372, an MTAP-selective, second-generation PRMT5 inhibitor exploiting synthetic lethality, with monotherapy dose escalation and expansions in all MTAP-deleted tumors plus focused cohorts in NSCLC and PDAC. Expansion includes BAY 3713372 alone and in combinations for NSCLC and PDAC; key cardiac comorbidities are excluded.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with FRα-positive metastatic/recurrent lung adenocarcinoma and malignant pleural effusion (ECOG 0–1, prior systemic therapy) receive cyclophosphamide/fludarabine lymphodepletion followed by a single intrapleural infusion of autologous MOv19-BBz CAR T cells targeting folate receptor‑alpha (second‑generation CAR with 4‑1BB/CD3ζ). Candidates must be eligible for standard checkpoint inhibitors (which may start ≥28 days post‑CAR T) and have controlled CNS disease; key exclusions include extensive parenchymal lung involvement beyond one lobe, significant undrainable effusion, ILD/pneumonitis, active hepatitis, and autoimmune disease requiring immunosuppression.
ClinicalTrials.gov ID: NCT07116057
TrialFetch AI summary: Adults (ECOG 0–1) with refractory/recurrent locally advanced or metastatic solid tumors—particularly tissue factor–expressing cancers such as HNSCC, NSCLC, esophagogastric, colorectal, pancreatic ductal adenocarcinoma, cervical, endometrial, or urothelial carcinoma—after appropriate prior systemic therapy (prior-line limits vary by study part) are eligible. Treatment is STRO-004, a tissue factor–targeting antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given as monotherapy with dose escalation/expansion or combined with pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT07227168
TrialFetch AI summary: Enrolls adults with relapsed/refractory locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation (ECOG 0–1, measurable disease) after progression on, intolerance of, or ineligibility for standard approved therapies. Patients receive oral once-daily PLX-61639, a SMARCA2 targeted protein degrader (synthetic-lethal strategy in SMARCA4-deficient tumors; DCAF16-linked, proteasome-mediated SMARCA2 degradation).
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Enrolling adults (ECOG 0–1) with metastatic/unresectable solid tumors refractory to standard therapy (excluding melanoma, primary brain tumors/GBM, sarcoma, and pancreatic ductal adenocarcinoma; no active untreated brain mets), with expansion cohorts limited to ≤3 prior systemic lines and focused on PD-(L)1–naïve MSS colorectal cancer without liver metastases and PD-1 relapsed/refractory MSS endometrial cancer, RCC, or NSCLC. Patients receive IV ADU-1805 (anti-SIRPα mAb blocking the SIRPα–CD47 “don’t eat me” checkpoint to enhance myeloid/macrophage activity) every 3 weeks alone or with fixed-dose pembrolizumab every 3 weeks.
ClinicalTrials.gov ID: NCT05856981
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic solid tumors harboring a KRAS alteration (mutation or amplification) who have progressed on, are ineligible for, or declined standard-of-care therapy (Arm D additionally requires PD-L1 TPS ≥50%; excludes untreated CNS metastases and ILD/pneumonitis). Participants receive the first-in-human agent BMS-986523 (target/mechanism not publicly described) as monotherapy or combined with pembrolizumab (anti–PD-1), cetuximab (anti-EGFR), or gemcitabine plus nab-paclitaxel.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced/metastatic measurable solid tumors harboring any KRAS mutation or wild-type KRAS amplification (ECOG 0–1) after 1–4 prior systemic regimens are treated with IV PT0511 monotherapy in dose-escalation/expansion cohorts; a colorectal cancer expansion cohort receives PT0511 plus cetuximab (anti-EGFR). PT0511 is an investigational KRAS-altered tumor–directed agent, but its specific molecular mechanism/allele selectivity is not publicly specified.
ClinicalTrials.gov ID: NCT07300150
TrialFetch AI summary: Adults with unresectable locally advanced/metastatic EGFR-mutant NSCLC (ECOG 0–1) with progression after prior first- or second-line osimertinib (alone or with chemotherapy), excluding those with other actionable drivers or known EGFR osimertinib-resistance mutations. Treatment is continued osimertinib plus escalating-dose oral NXP900 (eCF506), a selective SRC-family kinase inhibitor (high potency vs YES1; also SRC) designed to lock kinases in an inactive conformation to address resistance biology.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293